The ViRobTM technology is a revolutionary autonomous micro-robot designed to be controlled remotely or from within the body.

ViRobTM Platform

The ViRobTM technology is a revolutionary autonomous micro-robot designed to operate within natural and artificial lumens, which can be controlled remotely or from within the body. It’s miniature dimensions allowing it to navigate in different spaces within the human body, including blood vessels, the digestive tract and the respiratory system. Its unique structure gives it the ability to move in tight spaces and execute turns as well as the ability to remain within the human body for prolonged time.

ViRobTM’s First Application: Self-Cleaning Shunt for Hydrocephalus Patients

Self-Cleaning Shunt (SCSTM)

Effectiveness of SCSTM to prevent shunt blockage

Market Facts

Hydrocephalus, also known as “water in the brain,” is a medical condition, presented mostly in babies, in which there is an abnormal accumulation of cerebrospinal fluid (CSF) in the ventricles of the brain. The same condition, known as normal pressure hydrocephalus (NPH), presented mostly in the elderly population, causes thinking and reasoning problems, difficulty walking, etc.

  • Hydrocephalus occurs in about 1 in every 500 births in the U.S. alone (1,2)
  • Over 1,000,000 people in the United States currently live with hydrocephalus (1)
  • It is estimated that more than 700,000 Americans have NPH, but less than 20% receive an appropriate diagnosis (1)
  • The problem is often misdiagnosed as Dementia, Alzheimer’s, or Parkinson’s (2)
  • NPH can cause dementia, difficulty in walking and, urinary incontinence (2)
  • Approximately 50% of shunts in the pediatric population fail within two years of placement and repeated operations are often required (3)
  • Ventricular catheter blockage is by far the most frequent events (4)

Our Solution

The Microbot SCS™ device is a robotic system designed as the ventricular catheter portion of a CSF shunt system. Microbot’s ventricular catheter can connect to existing valves currently on the market and maintain CSF flow through the ventricular catheter. It is expected that the SCS™ device will replace all ventricular catheters, while drastically reducing, and potentially eliminating, shunt occlusions.


(1) NIH, National Institute of Neurological Disorders and Stroke.

(2) National Hydrocephalus Foundation.

(3) Hydrocephalus Association.

(4) World Federation of Neurological Societies.

Laboratory Testing of Self-Cleaning Shunt


  • UK Shunt Testing Lab, Cambridge University, UK:
    Goal: Test hydrodynamic resistance of the Company’s SCS™.
    Results: Confirms that SCS™ device maintains hydrodynamic performance of the adjustable hydrocephalus valves.
  • Wayne State University:
    Goal: Test and finalize the design of the Company’s SCS, using Dr. Carolyn Harris’ bioreactor system that mimics the human brain tissue three dimensionally.
    Results: Supports the SCS’s potential as a viable technology for preventing occlusion in shunts used to treat hydrocephalus.
  • Washington University:
    Goal: Develop the protocol for and to execute the necessary animal study to determine the effectiveness of the company’s SCS prototype.
    Result: Met the primary goal to determine the safety of the company’s SCS™ device.